These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1990782)

  • 1. Role of new anticoagulants as adjunctive therapy during thrombolysis.
    Eisenberg PR
    Am J Cardiol; 1991 Jan; 67(3):19A-24A. PubMed ID: 1990782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts in coronary thrombolysis.
    Eisenberg PR
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1161-70. PubMed ID: 1400079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Principles underlying the use of conjunctive agents with plasminogen activators.
    Shebuski RJ
    Ann N Y Acad Sci; 1992 Dec; 667():382-94. PubMed ID: 1309058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.
    Scharfstein JS; Abendschein DR; Eisenberg PR; George D; Cannon CP; Becker RC; Sobel B; Cupples LA; Braunwald E; Loscalzo J
    Am J Cardiol; 1996 Sep; 78(5):503-10. PubMed ID: 8806332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antithrombin therapy in acute coronary syndromes].
    Maseri A; Andreotti F; Biasucci LM; Rebuzzi AG
    Cardiologia; 1994 Dec; 39(12 Suppl 1):7-13. PubMed ID: 7634317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).
    Peters RJ; Spickler W; Théroux P; White H; Gibson M; Molhoek PG; Anderson HV; Weitz JI; Hirsh J; Weaver WD
    Am Heart J; 2001 Aug; 142(2):237-43. PubMed ID: 11479461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis, anticoagulation, and reocclusion.
    Rapaport E
    Am J Cardiol; 1991 Dec; 68(16):17E-22E. PubMed ID: 1746447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New anticoagulants: current status and future potential.
    Weitz JI; Crowther MA
    Am J Cardiovasc Drugs; 2003; 3(3):201-9. PubMed ID: 14727932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of new antiplatelet agents as adjunctive therapies in thrombolysis.
    Willerson JT; Golino P; McNatt J; Eidt J; Yao SK; Buja LM
    Am J Cardiol; 1991 Jan; 67(3):12A-18A. PubMed ID: 1990781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of heparin in coronary thrombolysis.
    Eisenberg PR
    Chest; 1992 Apr; 101(4 Suppl):131S-139S. PubMed ID: 1555478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in antithrombin therapy for ST-elevation myocardial infarction.
    Chen WH; Lau CP
    Chin Med J (Engl); 2003 Nov; 116(11):1760-3. PubMed ID: 14642154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
    French JK; Edmond JJ; Gao W; White HD; Eikelboom JW
    Am J Cardiovasc Drugs; 2004; 4(2):107-15. PubMed ID: 15049722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New anticoagulant strategies.
    Weitz J; Hirsh J
    J Lab Clin Med; 1993 Oct; 122(4):364-73. PubMed ID: 8228551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulants in coronary artery disease.
    Lee LV
    Cardiol Clin; 2008 Nov; 26(4):615-28. PubMed ID: 18929235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
    Carswell CI; Plosker GL
    Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of blood coagulation by plaque rupture: mechanisms and prevention.
    Weitz JI
    Am J Cardiol; 1995 Feb; 75(6):18B-22B. PubMed ID: 7863966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging anticoagulants: mechanism of action and future potential.
    Klement P; Rak J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of reocclusion after coronary thrombolysis.
    Eisenberg PR
    Z Kardiol; 1993; 82 Suppl 2():175-8. PubMed ID: 8328198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.